Yutaka Yamamoto

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 23

Top Venues

Breast cancer (Tokyo, Japan)

Cancer science

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Diagnostics (Basel, Switzerland)

Kumamoto University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Kumamoto University Jul 01 2000

Japan

Associate Professor :: Breast and Endocrine Surgery

Publications

Masaya Hattori, Naoko Honma, Shigenori Nagai, Kazutaka Narui, Tomoko Shigechi, Yukinori Ozaki, Masayuki Yoshida, Takashi Sakatani, Eiichi Sasaki, Yuko Tanabe, Junji Tsurutani, Toshimi Takano, Shigehira Saji, Shinobu Masuda, Rie Horii, Hitoshi Tsuda, Rin Yamaguchi, Tatsuya Toyama, Chikako Yamauchi, Masakazu Toi, Yutaka Yamamoto
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast cancer (Tokyo, Japan) (2024)
Yutaka Yamamoto, Chikako Yamauchi, Tatsuya Toyama, Shigenori Nagai, Takehiko Sakai, Goro Kutomi, Michio Yoshimura, Masaaki Kawai, Shoichiro Ohtani, Kazunori Kubota, Kazutaka Nakashima, Naoko Honma, Masayuki Yoshida, Eriko Tokunaga, Naruto Taira, Hiroji Iwata, Shigehira Saji
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Yutaka Yamamoto, Chikako Yamauchi, Tatsuya Toyama, Shigenori Nagai, Takehiko Sakai, Goro Kutomi, Michio Yoshimura, Masaaki Kawai, Shoichiro Ohtani, Kazunori Kubota, Kazutaka Nakashima, Naoko Honma, Masayuki Yoshida, Eriko Tokunaga, Naruto Taira, Hiroji Iwata, Shigehira Saji
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Masaya Hattori, Naoko Honma, Shigenori Nagai, Kazutaka Narui, Tomoko Shigechi, Yukinori Ozaki, Masayuki Yoshida, Takashi Sakatani, Eiichi Sasaki, Yuko Tanabe, Junji Tsurutani, Toshimi Takano, Shigehira Saji, Shinobu Masuda, Rie Horii, Hitoshi Tsuda, Rin Yamaguchi, Tatsuya Toyama, Chikako Yamauchi, Masakazu Toi, Yutaka Yamamoto
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Masaya Hattori, Naoko Honma, Shigenori Nagai, Kazutaka Narui, Tomoko Shigechi, Yukinori Ozaki, Masayuki Yoshida, Takashi Sakatani, Eiichi Sasaki, Yuko Tanabe, Junji Tsurutani, Toshimi Takano, Shigehira Saji, Shinobu Masuda, Rie Horii, Hitoshi Tsuda, Rin Yamaguchi, Tatsuya Toyama, Chikako Yamauchi, Masakazu Toi, Yutaka Yamamoto
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Masaya Hattori, Naoko Honma, Shigenori Nagai, Kazutaka Narui, Tomoko Shigechi, Yukinori Ozaki, Masayuki Yoshida, Takashi Sakatani, Eiichi Sasaki, Yuko Tanabe, Junji Tsurutani, Toshimi Takano, Shigehira Saji, Shinobu Masuda, Rie Horii, Hitoshi Tsuda, Rin Yamaguchi, Tatsuya Toyama, Chikako Yamauchi, Masakazu Toi, Yutaka Yamamoto
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Yutaka Yamamoto, Chikako Yamauchi, Tatsuya Toyama, Shigenori Nagai, Takehiko Sakai, Goro Kutomi, Michio Yoshimura, Masaaki Kawai, Shoichiro Ohtani, Kazunori Kubota, Kazutaka Nakashima, Naoko Honma, Masayuki Yoshida, Eriko Tokunaga, Naruto Taira, Hiroji Iwata, Shigehira Saji
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Masaya Hattori, Naoko Honma, Shigenori Nagai, Kazutaka Narui, Tomoko Shigechi, Yukinori Ozaki, Masayuki Yoshida, Takashi Sakatani, Eiichi Sasaki, Yuko Tanabe, Junji Tsurutani, Toshimi Takano, Shigehira Saji, Shinobu Masuda, Rie Horii, Hitoshi Tsuda, Rin Yamaguchi, Tatsuya Toyama, Chikako Yamauchi, Masakazu Toi, Yutaka Yamamoto
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Yutaka Yamamoto, Chikako Yamauchi, Tatsuya Toyama, Shigenori Nagai, Takehiko Sakai, Goro Kutomi, Michio Yoshimura, Masaaki Kawai, Shoichiro Ohtani, Kazunori Kubota, Kazutaka Nakashima, Naoko Honma, Masayuki Yoshida, Eriko Tokunaga, Naruto Taira, Hiroji Iwata, Shigehira Saji
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast cancer (Tokyo, Japan) (2024)
Yutaka Yamamoto, Chikako Yamauchi, Tatsuya Toyama, Shigenori Nagai, Takehiko Sakai, Goro Kutomi, Michio Yoshimura, Masaaki Kawai, Shoichiro Ohtani, Kazunori Kubota, Kazutaka Nakashima, Naoko Honma, Masayuki Yoshida, Eriko Tokunaga, Naruto Taira, Hiroji Iwata, Shigehira Saji
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Yutaka Yamamoto, Chikako Yamauchi, Tatsuya Toyama, Shigenori Nagai, Takehiko Sakai, Goro Kutomi, Michio Yoshimura, Masaaki Kawai, Shoichiro Ohtani, Kazunori Kubota, Kazutaka Nakashima, Naoko Honma, Masayuki Yoshida, Eriko Tokunaga, Naruto Taira, Hiroji Iwata, Shigehira Saji
Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast cancer (Tokyo, Japan) (2024)
Yutaka Yamamoto, Chikako Yamauchi, Tatsuya Toyama, Shigenori Nagai, Takehiko Sakai, Goro Kutomi, Michio Yoshimura, Masaaki Kawai, Shoichiro Ohtani, Kazunori Kubota, Kazutaka Nakashima, Naoko Honma, Masayuki Yoshida, Eriko Tokunaga, Naruto Taira, Hiroji Iwata, Shigehira Saji
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Yutaka Yamamoto, Chikako Yamauchi, Tatsuya Toyama, Shigenori Nagai, Takehiko Sakai, Goro Kutomi, Michio Yoshimura, Masaaki Kawai, Shoichiro Ohtani, Kazunori Kubota, Kazutaka Nakashima, Naoko Honma, Masayuki Yoshida, Eriko Tokunaga, Naruto Taira, Hiroji Iwata, Shigehira Saji
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast cancer (Tokyo, Japan) 31 (3) (2024)
Ian E Krop, Norikazu Masuda, Toru Mukohara, Shunji Takahashi, Takahiro Nakayama, Kenichi Inoue, Hiroji Iwata, Yutaka Yamamoto, Ricardo H Alvarez, Tatsuya Toyama, Masato Takahashi, Akihiko Osaki, Shigehira Saji, Yasuaki Sagara, Joyce O'Shaughnessy, Shoichi Ohwada, Kumiko Koyama, Tatsuya Inoue, Li Li, Parul Patel, Joseph Mostillo, Yoshimi Tanaka, David W Sternberg, Dalila Sellami, Kan Yonemori
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Yoshihiro Komohara, Daisuke Kurotaki, Hirotake Tsukamoto, Yuko Miyasato, Hiromu Yano, Cheng Pan, Yutaka Yamamoto, Yukio Fujiwara
Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes. Cancer science (2023)
Yoshihiro Komohara, Daisuke Kurotaki, Hirotake Tsukamoto, Yuko Miyasato, Hiromu Yano, Cheng Pan, Yutaka Yamamoto, Yukio Fujiwara
Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes. Cancer science (2023)
Yutaka Yamamoto, Hiroji Iwata, Naruto Taira, Norikazu Masuda, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Tomomi Fujisawa, Naoki Niikura, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS). Cancer science 113 (9) (2022)
Aiko Sueta, Mutsuko Yamamoto-Ibusuki, Mai Tomiguchi, Yoshitaka Fujiki, Lisa Goto-Yamaguchi, Hirotaka Iwase, Yutaka Yamamoto
Predictive and prognostic significance of BRCAness in HER2-negative breast cancer. Breast cancer (Tokyo, Japan) 29 (2) (2022)
Yutaka Yamamoto, Hiroyasu Yamashiro, Andreas Schneeweiss, Volkmar Müller, Oleg Gluz, Peter Klare, Bahriye Aktas, Dank Magdolna, László Büdi, Béla Pikó, László Mangel, Masakazu Toi, Satoshi Morita, Shinji Ohno
Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies. Breast cancer (Tokyo, Japan) (2022)
Naruto Taira, Masataka Sawaki, Yukari Uemura, Tsuyoshi Saito, Shinichi Baba, Kokoro Kobayashi, Hiroaki Kawashima, Michiko Tsuneizumi, Noriko Sagawa, Hiroko Bando, Masato Takahashi, Miki Yamaguchi, Tsutomu Takashima, Takahiro Nakayama, Masahiro Kashiwaba, Toshiro Mizuno, Yutaka Yamamoto, Hiroji Iwata, Yasuo Ohashi, Hirofumi Mukai, Takuya Kawahara, null null
Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (22) (2021)
Shi Qui, Takashi Takeshita, Aiko Sueta, Mai Tomiguchi, Lisa Goto-Yamaguchi, Kaori Hidaka, Ikuko Suzu, Yutaka Yamamoto, Hirotaka Iwase
Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum. Breast cancer (Tokyo, Japan) 28 (3) (2021)
Yoshimasa Kosaka, Yutaka Yamamoto, Hirokazu Tanino, Hiroshi Nishimiya, Mutsuko Yamamoto-Ibusuki, Yuko Hirota, Hirotaka Iwase, Seigo Nakamura, Sadako Akashi-Tanaka
BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. Diagnostics (Basel, Switzerland) 10 (2) (2020)
Yutaka Yamamoto, Hiroyasu Yamashiro, Uhi Toh, Naoto Kondo, Rikiya Nakamura, Masahiro Kashiwaba, Masato Takahashi, Koichiro Tsugawa, Takashi Ishikawa, Takahiro Nakayama, Shoichiro Ohtani, Toshimi Takano, Tomomi Fujisawa, Tatsuya Toyama, Hidetoshi Kawaguchi, Kojiro Mashino, Yuichi Tanino, Satoshi Morita, Masakazu Toi, Shinji Ohno
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. Breast cancer (Tokyo, Japan) 28 (1) (2020)

Yutaka Yamamoto.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yutaka Yamamoto